jr-141
Recombinant proteinexperimental
Clinical trial activity
7 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
5
Phase 3
4
Phase 4
0
Earliest trial started Mar 30, 2017 (NCT03128593)
Timeline
Indications
Studied for
Mechanism of action
- Iduronate 2-sulfataseSupplementation
IDS supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- jr-141
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05594992 | Phase 3 | Feb 1, 2023 | JCR Pharmaceuticals Co., Ltd. |
| NCT04573023 | Phase 3 | Nov 30, 2021 | JCR Pharmaceuticals Co., Ltd. |
| NCT04348136 | Phase 2/Phase 3 (Phase 3) | Sep 1, 2019 | JCR Pharmaceuticals Co., Ltd. |
| NCT03708965 | Phase 2 | Jan 1, 2019 | JCR Pharmaceuticals Co., Ltd. |
| NCT03568175 | Phase 2/Phase 3 (Phase 3) | Aug 1, 2018 | JCR Pharmaceuticals Co., Ltd. |
| NCT03359213 | Phase 2 | Jul 26, 2018 | JCR Pharmaceuticals Co., Ltd. |
| NCT03128593 | Phase 1/Phase 2 (Phase 2) | Mar 30, 2017 | JCR Pharmaceuticals Co., Ltd. |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| JCR Pharmaceuticals Co., Ltd. | For profit | 7 | 7 | 2 | 2017 |
1 organizations
Page 1 / 1